COVID-19: THE EUROPEAN COMMISSION AUTHORIZES A THIRD VACCINE FOR THE AUTUMN

The European Commission has authorized the vaccine COVID-19 adapted to Nuvaxovid XBB.1.5, developed by Novavax Pharmaceuticals. This is another important step in the fight against the disease. This is the first adapted protein-based vaccine licensed for this fall and winter season.

The vaccine fights the Omicron XBB.1.5 subvariant of the SARS-CoV-2 virus.

The European Medicines Agency (EMA) conducted an in-depth evaluation of the vaccine. Following this evaluation, the Commission authorized the adapted vaccine under an accelerated procedure to allow Member States sufficient time to prepare their autumn-winter vaccination campaigns.

In accordance with previous recommendations of the EMA and the European Centre for Disease Prevention and Control (ECDC), adults and adolescents aged 12 years and older who require vaccination are invited to receive a single dose, regardless of their history of vaccination against COVID-19.

This text was originally published in Aquí Europa.